SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Synthorx, Inc. – (NasdaqGS: THOR)

BALA CYNWYD, December 10, 2019 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synthorx, Inc. (“Synthorx” or “the Company”) (NasdaqGS:THOR) for possible breaches of fiduciary duty and other violations of federal and state law in connection with proposed acquisition of the Company by Sanofi (NASDAQ GS:SNY). Under the terms of the agreement, Synthorx shareholders will receive only $68.00 for each share of Synthorx common stock owned.

The investigation concerns whether the Synthorx Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Sanofi is underpaying for the Company. For example, the drug at the center of the deal is Synthorx’s investigational medicine code-named THOR-707. Meant to treat solid tumors, the drug is designed to boost the number of cancer-fighting cells in the body, potentially overwhelming the disease with effector T-cells and natural killer cells.

If you own shares of Synthorx stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.